Dimerix Limited Stock price

Equities

DXB

AU000000DXB7

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
0.3 AUD -1.64% Intraday chart for Dimerix Limited -7.69% +46.34%
Sales 2022 6.47M 4.21M Sales 2023 8.98M 5.85M Capitalization 24.06M 15.68M
Net income 2022 -10M -6.52M Net income 2023 -13M -8.47M EV / Sales 2022 4.48 x
Net cash position 2022 9.56M 6.23M Net cash position 2023 2.03M 1.33M EV / Sales 2023 2.45 x
P/E ratio 2022
-3.37 x
P/E ratio 2023
-1.46 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 67.92%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.64%
1 week-7.69%
Current month+33.33%
1 month+42.86%
3 months+42.86%
6 months+376.19%
Current year+46.34%
More quotes
1 week
0.29
Extreme 0.29
0.34
1 month
0.20
Extreme 0.197
0.37
Current year
0.16
Extreme 0.16
0.37
1 year
0.05
Extreme 0.052
0.37
3 years
0.05
Extreme 0.052
0.48
5 years
0.05
Extreme 0.052
0.78
10 years
0.05
Extreme 0.052
0.78
More quotes
Managers TitleAgeSince
Chief Executive Officer - 18-08-26
Director of Finance/CFO - 19-05-05
Chief Tech/Sci/R&D Officer - 23-10-22
Members of the board TitleAgeSince
Chief Executive Officer - 18-08-26
Director/Board Member - 17-04-30
Chairman - 23-01-11
More insiders
Date Price Change Volume
24-03-28 0.3 -1.64% 2 683 913
24-03-27 0.305 +3.39% 4,322,774
24-03-26 0.295 -1.67% 4,031,983
24-03-25 0.3 -6.25% 6,132,192
24-03-22 0.32 -5.88% 3,700,270

Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT

More quotes
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing new therapies in areas with unmet medical needs for global markets. It is focused on developing its products, DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its DMX-200 and DMX-700 are identified using its assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. It has completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease. Receptor-HIT is licensed to Excellerate Bioscience.
More about the company
  1. Stock
  2. Equities
  3. Stock Dimerix Limited - Australian S.E.